Literature DB >> 26628964

Optimization modeling of single-chain antibody against hepatoma based on similarity algorithm.

Zhi-Jun Zhao1, Jing-Tao Chen1, Jia-Ying Yuan2, Xiao-Xiang Yin1, Hua-Yong Song1, Xin-Chun Wang1.   

Abstract

The purposes was to establish optimal modeling of single-chain antibody molecules based on similarity algorithm and seek the connecting peptides that had the minimal effect on the structure and bioactivity of the variable region of heavy chain (VH) and that of light chain (VL) in a single-chain antibody against liver cancer. After the Linker with different lengths (n=0~7) had been added into single chain fragment variable (ScFv), modeling of the overall sequences of VH, VL and ScFv were conducted respectively. Meanwhile, the peptide chain structure of (Gly4Ser)n was adopted for the connecting peptide. Then the spatial spherical shell layer alignment algorithm based on spherical polar coordinates was utilized for comparing the structural similarity of VH and VL before and after adding connecting peptide. Equally, in order to determine the stability of VH and VL, MATLAB was applied for analysis of the fore and aft distances and the diffusion radius. Indirect ELISA method was used to detect single-chain antibody immunological activity of Linker with different lengths. The MTT assay was utilized for the examination of the inhibition rate of single-chain antibody with different lengths of Linker to liver cancer cell. When n=4, the structural similarity between VH together with VL and their original ones was the highest. When n=3, the influence of connecting peptide on the stability of VH and VL was minimum. When n>3, the fore and aft distances changed little due to the increase and fold of the length of peptide chain. The results of ELISA detection showed that when n=4, affinity of single chain antibody to liver cancer cells was much higher. The MTT test also indicated that when n=4, the inhibition rate of the connecting peptide on hepatoma carcinoma cell reached the highest, and that came second when n=3. When n=4, the structural stability and biological functions of anti-hepatoma single-chain antibody were both favorable. This study has provided a basis for the design and construction of single-chain antibody.

Entities:  

Keywords:  HscFv4-16; connecting peptide; modeling; optimization; similarity algorithm

Year:  2015        PMID: 26628964      PMCID: PMC4658853     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  21 in total

Review 1.  Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.

Authors:  Nina E Weisser; J Christopher Hall
Journal:  Biotechnol Adv       Date:  2009-04-15       Impact factor: 14.227

2.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

Review 3.  Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.

Authors:  John M Luk; Kwong-Fai Wong
Journal:  Clin Exp Pharmacol Physiol       Date:  2006 May-Jun       Impact factor: 2.557

4.  Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4.

Authors:  Alexandre Fontayne; Karen Vanhoorelbeke; Inge Pareyn; Isabel Van Rompaey; Muriel Meiring; Seb Lamprecht; Jan Roodt; Johan Desmet; Hans Deckmyn
Journal:  Thromb Haemost       Date:  2006-11       Impact factor: 5.249

5.  Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody.

Authors:  Fabrice Le Gall; Uwe Reusch; Melvyn Little; Sergey M Kipriyanov
Journal:  Protein Eng Des Sel       Date:  2004-05-04       Impact factor: 1.650

6.  Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

Authors:  Robert G Gish; Camillo Porta; Lucian Lazar; Paul Ruff; Ronald Feld; Adina Croitoru; Lynn Feun; Krzysztof Jeziorski; John Leighton; José Gallo; Gerard T Kennealey
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

7.  High-level secretion of recombinant monomeric murine and human single-chain Fv antibodies from Drosophila S2 cells.

Authors:  Allissia A Gilmartin; Benjamin Lamp; Till Rümenapf; Mats A A Persson; Félix A Rey; Thomas Krey
Journal:  Protein Eng Des Sel       Date:  2011-12-12       Impact factor: 1.650

8.  Construction, purification, and characterization of a chimeric TH1 antagonist.

Authors:  Iraldo Bello-Rivero; Yeny Torrez-Ruiz; Elizabeth Blanco-Garcés; Giselle Pentón-Rol; Osmani Fernández-Batista; Luís Javier-González; Haydee Gerónimo-Perez; Pedro López-Saura
Journal:  BMC Biotechnol       Date:  2006-05-22       Impact factor: 2.563

9.  p42.3 gene expression in gastric cancer cell and its protein regulatory network analysis.

Authors:  Jianhua Zhang; Chunlei Lu; Zhigang Shang; Rui Xing; Li Shi; Youyong Lv
Journal:  Theor Biol Med Model       Date:  2012-12-11       Impact factor: 2.432

10.  Construction and high cytoplasmic expression of a tumoricidal single-chain antibody against hepatocellular carcinoma.

Authors:  Duanpen Sandee; Sumalee Tungpradabkul; Manae Tsukio; Tadayuki Imanaka; Masahiro Takagi
Journal:  BMC Biotechnol       Date:  2002-09-12       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.